Loading company…
RiboTech develops lariat and circular mRNA-based therapeutics, including vaccines.
RiboTech researches mRNA therapies using lariat and circular structures, including vaccines for infectious diseases and cancer. Founded in 2022 and based in Seoul, the company raised KRW 2.5 billion in pre-Series A funding in January 2025 from DAYLI Partners and Union Investment Partners. The funding is intended to advance a lariat mRNA-based anticancer vaccine.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in